Published in Hepatitis Weekly, September 6th, 1999
Lamivudine, a nucleoside analogue, is a potent inhibitor of HBV replication, but it is associated with a 14-39 percent rate of resistance.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.